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The natural history and treatment of experimental endocarditis due to heterogeneous and
homogeneous methicillin-resistant Staphylococcus epidermidis was investigated. Amoxicillin/
clavulanate or vancomycin were administered for 3 days via a computerized pump to mimic
human drug kinetics in animals. After challenge with the minimum inoculum producing 90% of
infections (ID9o) , bacteria in the vegetations grew logarithmically for 16 h. Then, bacterial densi-
ties stabilized (at -108 cfu/g) and growth rates sharply declined. Both regimens cured ~60% of
endocarditis (due to heterogeneous or homogeneous bacteria) when started 12-16 h after infec-
tion, although the bacterial densities in the vegetations had increased by 20 times in between. In
contrast, treatment started after 24 h failed in most animals, while bacterial densities had not
increased any more. Thus, while both regimens were equivalent, the therapeutic outcome was
best predicted by growth rates in the vegetations, not by bacterial densities. These observations
highlight the importance of phenotypic tolerance developing in vivo.
In the early 1940s, the introduction of penicillin in medi-
cine was rapidly followed by the emergence of penicillinase-
producing penicillin-resistant staphylococci, posing the first
major challenge to the then-nascent era ofantimicrobial che-
motherapy [I]. Twenty years later this scenario was partially
repeated when it appeared that antibiotic pressure with the
newly available penicillinase-stable methicillin selected for a
new, so-called intrinsic type of resistance to ,8-lactams [2].
Intrinsic resistance to methicillin was not due to penicillin-
ase production but appeared to require the production of a
new, unique, penicillin-binding protein (PBP) with low ,8-
lactam affinity (called PBP 2A or 2') in addition to the nor-
mal set ofstaphylococcal PBPs [3,4]. PBP 2A is also consid-
ered to be responsible for cross-resistance to most other
,8-lactam antibiotics (for review see [5]).
Today, methicillin resistance is genuinely ubiquitous in
hospital isolates of staphylococci. In Switzerland, for in-
stance, 40%-60% of hospital isolates of Staphylococcus epi-
dermidis are resistant to methicillin [6] (unpublished data).
Although less common, the frequency of methicillin-resis-
tant Staphylococcus aureus varies from 3%in our hospital [7]
to 20% in other hospitals of the country (Auckenthaler R,
personal communication). In the United States, up to 40%of
S. aureus isolates are resistant to methicillin in certain insti-
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tutions [8]. In addition, most of these organisms are resistant
to a number of other drugs [5, 9], posing a serious challenge
to antimicrobial therapy.
The only nonexperimental antibiotic to which methicillin-
resistant staphylococci are still considered uniformly sensi-
tive is vancomycin, which is potentially toxic and can be
given only parenterally (see [5]). However, staphylococci
may be on the verge of becoming totally resistant to any
available antibiotics, since it has been shown in the labora-
tory that vancomycin resistance could be transferred to S.
aureus from vancomycin-resistant enterococci [10]. Transfer
of vancomycin resistance into methicillin-resistant staphylo-
cocci would have major consequences for public health. To
decrease the risk of this occurrence, it is necessary both to
interfere with the spread of methicillin-resistant staphylo-
cocci and to develop alternative, nonglycopeptide antimicro-
bial agents to prevent selection of glycopeptide resistance in
such organisms.
The purpose of the present study was to investigate the
efficacy of the nonglycopeptide combination amoxicillin/
clavulanate in the treatment of experimental endocarditis
due to methicillin-resistant S. epidermidis(MRSE). The ratio-
nale of the experiments was based on the dual observations
that amoxicillin/clavulanate could cure experimental endo-
carditis due to methicillin-resistant S. aureus (MRSA) [II.
12] (presumably because of the relatively good affinity of
amoxicillin for PBP 2A [12]) and that a similar PBP 2A medi-
ates high level of methicillin resistance in both MRSA and
MRSE [13-15]. In addition, since the course of experimen-
tal endocarditis due to S. epidermidis appeared to be more
indolent and resulted in less mortality than with S. aureus,
we investigated the therapeutic outcome of treatment started
either early or relatively late after the induction of infection
in animals.
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Table 1. Principal characteristics of the methicillin-resistant S. epidermidis (MRSE) isolates.
Antibiotic susceptibility
MRSE isolate Source Penicillinase Slime Gentamicin Clindamycin Erythromycin Cotrimoxazole
1386 Wound infection + + R R R S
4890 Peritonitis + +++ S R R R
1468 Wound infection + S S S S
I386-Hom* Laboratory derivative + + R R R S
NOTE. Penicillinase and slime production were measured by semiquantitative methods [17, 18]. S, susceptible; R, resistant as determined by standard
disk diffusion method [19].
* Homogeneous.
Materials and Methods
Microbiologic Methods
Microorganisms and growth conditions. The principal char-
acteristics ofthe four strains ofMRSE used in these experiments
are summarized in table I. Strains MRSE 1386,4890, and 1468
were clinical isolates recovered from distinct geographic areas
and typically expressing so-called heterogeneous resistance to
methicillin. Strain MRSE 1386-Hom was a homogeneously
methicillin-resistant derivative of strain MRSE 1386, which had
,been selected by serial passage of the parent strain on methicil-
lin-containing medium as described [16]. Strain I386-Hom was
stable, as it appeared to retain its homogeneously resistant phe-
notype for up to 60 generations in the absence of antibiotic
pressure in vitro (see [16D. All 4 strains produced penicillinase
as assessed both by a positive nitrocefin test and by inactivation
ofamoxicillin using a described method [17]. The production of
slime was assessed by a semiquantitative method [18] and antibi-
otic susceptibilities were determined by standard disk diffusion
test [19].
Unless otherwise stated. the bacteria were grown at 35°C in
Mueller-Hinton broth (MHB; Difco, Detroit) supplemented
with 2% NaCl or on Columbia agar (C agar; Becton Dickinson,
Cockeysville, MD) supplemented with 4% NaCl. Stocks were
kept at -70°C in MHB supplemented with 10%glycerol.
Antibiotics. Amoxicillin and clavulanate (either individu-
ally or in a 5: I [wt/wt] ratio) and flucloxacillin were obtained
from Beecham Laboratories (Brockham Park, UK) and vanco-
mycin from Eli Lilly (Indianapolis).
Antibiotic susceptibility. MlCs ofseveral antibiotics were de-
termined by a standard macrobroth method [20] in MHB supple-
mented with calcium and 2%NaCl (as recommended for suscep-
tibility testing of MRSA [21Dusing 105 cfu/rnl, as an inoculum.
The MlC was defined as the lowest drug concentration inhibit-
ing visible bacterial growth after 24 h of incubation at 35°C. For
MlC determinations of the combination of arnoxicillin/
clavulanate, the drugs were used in a ratio of 2: I (wt/wt).
Population analysis profile. The phenotypic expression of
methicillin resistance in vitro was determined as described [12].
In brief, serial dilutions of MRSE cultures (in MHB supple-
mented with 2% NaCI) in the late exponential phase of growth
were inoculated onto C agar plates supplemented with 4% NaCl
and containing increasing concentrations ofeither methicillin or
amoxicillin/clavulanate. Clavulanate was used at a fixed con-
centration of 5 mg/L. Large (> 108 cfu) and smaller (10 6, 104,
and 102 cfu) bacterial numbers were plated. The numbers of
colonies growing on the antibiotic-containing plates were deter-
mined after 48-72 h ofincubation at 35°C. Curves of the popu-
lation analysis profile were generated by plotting the numbers of
colonies growing on the plates against the concentrations ofanti-
biotic in the plates.
In vitro time-kill curves. Series of flasks containing 20 mL of
fresh MHB (prewarmed at 35°C) supplemented with 2% NaCI
were inoculated with 1/100 (vol/vol) of an overnight culture of
bacteria (grown in the same medium) and incubated with aera-
tion in a shaking incubator (at 120 rpm). Antibiotics (either
amoxicillin/clavulanate or vancomycin) were added at different
times during the logarithmic or the stationary phase of growth,
and bacterial survival was followed by plating dilutions of the
cultures onto C agar plates supplemented with 2000 units of
penicillinase/ml, (Bacto-Penase concentrate; Difco). Final con-
centrations of antibiotics were chosen to mimic the peak serum
levels obtained in humans (or rats) during intravenous (iv) ther-
apy: 90 and 20 mg/L for amoxicillin and clavulanate, respec-
tively, and 40 mg/L for vancomycin. All measurements were
made in triplicate.
Animal Experiments
Production ofendocarditis and installation ofan infusion pump
device. Sterile aortic vegetations were produced in female Wis-
tar rats (180-200 g) as described [22]. In brief, the animals were
anesthetized and a polyethylene catheter (Guerbet Biomedical.
Louvres, France) was inserted via the right carotid artery across
the aortic valve. The catheter was secured with a silk ligature
and left in place for the remainder of the experiment. At the
same time, an iv line consisting of a sterile Silastic catheter (in-
side and outside diameters, 0.02 and 0.037 mm, respectively;
Dow Corning, Midland, MI) was inserted via the jugular vein
into the superior vena cava for the delivery of the antibiotics.
The distal portion of the catheter was brought to the skin of the
interscapular region and connected to a programmable infusion
pump device (Pump 44; Harvard Apparatus, South Natick, MA)
through a swivel that permitted the animals to move in an unre-
strained fashion in their cage. Bacterial endocarditis was in-
duced 24 h after catheterization by iv challenge of the animals
with various inocula.
Natural history of experimental endocarditis due to MRS£.
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To determine the minimum size of bacterial inoculum produc-
ing endocarditis in 90% of the rats (1090), groups of rats (8-10
animals) were challenged through a tail vein with 0.5 mL of
saline containing 103-106 cfu of each test organism. The ani-
mals were killed 24 h after inoculation. One milliliter of blood
was drawn and plated for quantitative blood cultures. The aortic
vegetations were sterilely dissected, weighed, homogenized in I
mL of saline, and serially diluted before plating for quantitative
cultures. The technique permitted the detection of?:210gJO cfu/
g of tissue. The spleens were also processed for quantitative cul-
tures as described. The numbers of colonies growing on the
plates were determined after incubation at 35°C for 48 h.
To determine the kinetics of bacterial growth in the animals,
groups ofrats challenged with either the 1090 or 10 X 1090 were
killed at various times after iv bacterial challenge and the blood,
vegetations, and spleens were cultured as described.
Treatment ofexperimental endocarditis. Groups of rats chal-
lenged with either the 1090 or lOX 1090 of various strains of
MRSE were treated with either flucloxacillin, amoxicillin/
clavulanate, or vancomycin (flucloxacillin was used instead of
methicillin because the latter antibiotic is no longer used in the
clinic). To simulate in animals the human serum kinetics during
standard iv treatment (i.e., 1.2 g four times daily for am oxicillin/
clavulanate and 1.0 g twice daily for vancomycin), these drugs
were delivered to the animals at changing flow rates using a
programmable pump device. This required the injection of
164.4 mg of amoxicillin/clavulanate (5: I [wt/wt] ratio )/kg
every 6 h (beginning with a bolus of80.0 mg/kg followed by the
progressively decreasing infusion of the remaining 84.4 mg/kg)
and 23.2 mg of vancomycin/kg delivered at changing flow rates
over a l2-h period. Flucloxacillin (200 mg/kg every 5 h) was
administered subcutaneously (sc).
Therapy was started at various times after bacterial inocula-
tion (see Results) and lasted for 3 days. The rats were sacrificed
12 h after the last antibiotic dose (when drug was no longer
detected in the blood), and endocarditis was evaluated quantita-
tively as described. Each therapeutic experiment was matched
against a control group of rats killed at the initiation of therapy.
Determination ofserum antibiotic concentrations. Serum lev-
els of antibiotics were determined in both uninfected and in-
fected rats (groups of 3-6 animals) at various time points during
and after antibiotic administration. Antibiotic concentrations
were measured by an agar diffusion bioassay using Bacillus subti-
lis ATeC 6633 for amoxicillin, flucloxacillin, and vancomycin
and Klebsiella pneumoniae ATCC 29665 plus 60 mg ofpenicil-
lin/L for clavulanate [23]. For standard curves, antibiotics were
diluted in pooled rat serum.
Expression of antibiotic resistance in vivo. To evaluate the
number of highly methicillin-resistant organisms present on the
valves at the onset of therapy, quantitative cultures of vegeta-
tions from control animals were plated on agar containing 25
mg of methicillin/L in parallel with cultures on plain medium.
In addition, the vegetations ofanimals treated with amoxicillin/
clavulanate were plated simultaneously on plain and antibiotic-
containing agar plates (containing 5 mg of clavulanate/L plus
either 25 or 100 mg ofamoxiciUin) to detect the possible emer-
gence of antibiotic-resistant organisms in vivo. This screening
was not done in vancomycin-treated animals.
Statistical analysis. The x2 test with Yates's correction was
used to compare the incidence ofvalvular and spleen infections.
Results
Antibiotic Determinations
Antibiotic susceptibility. Table 2 shows the MICs of sev-
eral antibiotics for the 4 isolates of MRSE plus I clinical
isolate of methicillin-sensitive S. epidermidis used as a con-
trol. Since most methicillin-resistant staphylococci express a
so-called heterogeneous type of resistance to ~-lactams, we
also determined the population analysis profile ofeach ofthe
test organisms on ~-lactam-containingplates (figure 1). All
three clinical isolates (MRSE 1386, 4890, and 1468) typi-
cally expressed heterogeneous resistance to methicillin (as
exemplified for strain MRSE 1386 in figure lA) and con-
·tained subpopulations ofbacteria able to grow on plates con-
taining 500-1000 mg of rnethicillin/L, Importantly, the pro-
file of methicillin resistance was not altered when
clavulanate (5 mg/L) was added to the medium. In contrast,
no bacteria could grow on plates containing >25 mg of
amoxicillin/L in the presence of clavulanate (5 rngjL). Fig-
ure 1B shows that serial passage of the parent strain MRSE
1386 on methicillin resulted in a derivative (MRSE 1386-
Hom) that was homogeneously resistant to methicillin, that
Table 2. Phenotype of methicillin resistance and MICs of methicillin-resistant S. epidermidis (MRSE) test organisms to various antibi-
otics.
MIC (mg/L)
MRSE isolate Phenotype Methicillin Flucloxacillin Amoxicillin Clavulanate Amoxicillinjclavulanate Vancomycin
1386 Het >128 128 64 >128 8 2
4890 Het 128 32 32 >128 4 2
1468 Het >128 64 64 >128 4 2
1386 Hom >128 >128 >64 >128 8 4
90* S 0.5 0.5 >64 NO 0.5 1
NOTE. Het, heterogeneously resistant; Hom, homogeneously resistant to methicillin; NO, not determined.
* Clinical isolate of methicillin-susceptible (S) S. epidermidis (producing penicillinase) used as control.
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Figure 1. Population analysis profile
of heterogeneously methicillin-resistant
S. epidermidis isolate 1386 (A) and its
homogeneously resistant derivative
1386-Hom (B). Bacteria (» 108 cfu)
were plated on Columbia agar supple-
mented with 4% NaCl and twofold serial
dilutions of either methicillin (0),
amoxicillin (0), methicillin/clavulanate
(.), or arnoxicillin/clavulanate (.).
Clavulanate was used at fixed concen-
tration of 5 mg/L. Heterogeneous pro-
file of I 386-Hom on amoxicillin alone
was most likely due to residual penicil-
linase secretion by bacteria.
.1 10 100 1000
Antibiotic concentration (mg/I)
is, all colony-forming units in the bacterial population ex-
pressed high-level resistance to the drug. The homogeneous
derivative was also homogeneously susceptible to amoxicil-
lin in the presence of clavulanate. In contrast, when plated
on amoxicillin alone, some heterogenicity was observed.
This was most likely because of production of penicillinase
by the bacteria, which resulted in degradation of amoxicillin
in situ.
Antibiotic serum levels. After one injection of'flucloxacil-
lin (200 mg/kg sc), both the peak serum levels (124.3 mg/L)
and the half-life of the drug (0.5 h) were comparable to those
observed during iv therapy in humans (125.2 mg/L and 0.5
h, respectively [24]). After continuous infusion, serum levels
of amoxicillin, clavulanate, and vancomycin closely fol-
lowed the human serum kinetics produced by iv injections of
I g of amoxicillin, 0.2 g of clavulanate, and I g of van comy-
cin [25, 26]. Serum levels in rats at 30 min and 2,4, and 6 h
were as follows: arnoxicillin, 89.4 ± 23, 13.9 ± 1.4, 3.5 ±
2.0, and 1.2 ± 0.9 mg/L: clavulanate, 13.4 ± 5.0, 2.1 ± 0.5,
1.1 ± 0.4, and 0.3 ± 0.1 mg/L; and vancomycin, 40.5 ± 6.0,
30.0 ± 4.9, 21.5 ± 8.9, and 15.4 ± 2.0 mg/L (and 3.7 ± 2.8
mg/L at 12 h).
Animal Studies
Natural history ofexperimental MRSE endocarditis. The
minimum bacterial inoculum producing endocarditis in 90%
ofthe rats (1090) was 105 cfu for all 4 strains. After challenge
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Figure 2. Natural course of experi-
mental endocarditis due to methicillin-
resistant S. epidermidis (MRSE) isolate
1386 in rats challenged with either 105
cfu (ID 90 , solid line) or 106 cfu (lOX
ID9o , dashed line). Each point repre-
sents mean ± SD of7-25 animals. Dou-
bling times were derived from the
growth curves on the graph. After chal-
lenge with lOX ID9o , bacterial growth
in vegetations stopped --6 h earlier than
after ID9o •
3224
~
Doubling-time: 1 h
; Doubling-time: >.. -- 1
,.t---r--- ------ ± ---- ...,
~ ~\
Transition phase
Doubling-time: > 10 h
8 10 12 16
Time (hours)
4
~ 1°1J8
1~ 6
1~ 4
1
2 --- --- - - --- ------- --------
o
with such an inoculum (solid line, figure 2), bacteria in the
vegetations first entered a phase of rapid division (generation
time, --1 h) that lasted until bacterial densities on the valves
had reached '"'"-' 108 cfu/g of vegetation, at r- 16 h after bacte-
rial challenge. At that time, the generation time progressively
decreased (by about I 0 times) and bacterial densities
reached a plateau. The proportion of animals with positive
blood cultures increased with the severity of valvular infec-
tion (from 36% to 53% and 72% at 12, 16, and 24 h, respec-
tively, for all 3 clinical isolates). In contrast, all the spleen
cultures were positive from the beginning, but total bacterial
numbers and densities in this organ remained relatively
stable over the course of the disease (log., cfu/g of spleen,
2.8-3.4).
After challenge with 106 cfu (i.e., 10 X ID 90 ; dashed line,
figure 2), the course of experimental endocarditis was
roughly parallel to that following injection of the ID90 but
the growth curve was globally shifted to the left.
Expression ofmethicillin resistance in vivo. Expression of
methicillin resistance in the vegetations of untreated rats did
not vary over time. For the 3 heterogeneously resistant clini-
cal isolates, the frequency ofbacterial subpopulations able to
grow on plates containing 25 mg of methicillin/L was 2-6 X
10-5 during the whole course of infection. Similar control
experiments with the derivative MRSE 1386-Hom showed
that the homogenous phenotype also persisted in vivo, as
100% of the bacteria recovered from the vegetations of un-
treated animals grew on plates containing 100 mg of methi-
cillin/L.
Therapeutic experiments. The rather indolent course of
MRSE endocarditis allowed us to investigate the efficacy of
antibiotherapy started either early ( 12 or 16 h after bacterial
challenge) or relatively late (24 h after inoculation). This
type oflate treatment was not possible in former experiments
done with MRSA isolates [II, 12] because the more aggres-
sive course of S. aureus endocarditis resulted in the prema-
ture deaths of many of the animals.
Figure 3 depicts the therapeutic efficacy of various antibi-
otic regimens against experimental endocarditis after chal-
lenge with the ID90 ofMRSE 1386, MRSE 4890, and MRSE
1468. According to the experimental design, antibiotic treat-
ment was started either 12, 16, or 24 h after bacterial chal-
lenge and lasted for 3 days. Animals were always sacrificed
12 h after the last antibiotic dose. As expected, treatment
with flucloxacillin failed against all three organisms. In con-
trast, both amoxicillin/clavulanate and vancomycin success-
fully treated most ofthe infected rats when started 12 or 16 h
after bacterial challenge. However, the therapeutic efficacy
of both regimens tended to decrease with delayed onset of
treatment and clearly failed (at least for MRSE 1386 and
MRSE 4890) when started 24 h after bacterial challenge.
Analysis of the vegetations showed that this drop in effec-
tiveness did not correlate well with the bacterial densities in
the valvular lesions but did correlate with the rate ofbacte-
rial growth in situ (figure 2, 3). Indeed, treatment started at
either 12 or 16 h resulted in practically similar cure rates
despite the fact that bacterial densities in the vegetations had
increased by 20 times between those time points. During this
time, bacterial growth was relatively fast (figures 2, 3). In
contrast, the cure rates decreased between 16 and 24 h, while
the rate of bacterial growth in situ had come to a virtual halt
(doubling time, ~ 10 h) and bacterial densities in the vegeta-
tions did not increase any more. Treatment failures were not
due to organisms resistant to amoxicillin/clavulanate, as bac-
teria recovered from the infected valves and directly plated
on antibiotic-containing agar had retained the sensitivity of
the original strain (data not shown). Thus, in the present
experiments, the therapeutic efficacy of amoxicillin/
clavulanate and vancomycin was best predicted by the rate
of bacterial growth in situ, not by the bacterial densities in
the vegetations.
To investigate how therapy might be affected by larger
inocula, groups of rats were inoculated with lOX ID90 ( I06
cfu) of strain MRSE 1386 and treated as described. As
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Figure 3. Antibiotic treatment of ex-
perimental endocarditis in rats infected
with 105 cfu (ID 90) of methicillin-resis-
tant S. epidermidis isolates 1386 (top),
4890 (center), and 1468 (bottom).
MBD, median bacterial densities. Vege-
tations were considered sterile when no
growth occurred from cultures of undi-
luted homogenates. Numbers of ani-
mals in each group are indicated at
bottom of columns. C control; F, f1u-
cloxacillin; A/C amoxicillin/clavula-
nate; V, vancomycin; NS, not signifi-
cant.
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Figure 4. Antibiotic treatment of experimental endocarditis in
rats infected with 106 cfu (lOX ID90) of methicillin-resistant S.
epidermidis isolate 1386. See figure 3 legend for details.
shown in figure 2 (dashed line), after challenge with this
larger inoculum, the bacterial densities in the vegetations
attained the plateau (-., 108 cfu/g) sooner than after inocula-
tion with the 1090 (presumably because the valves had been
originally colonized with more bacteria after this larger inocu-
lum, as in experimental streptococcal endocarditis [27]) and
bacterial growth in situ already came to a halt 10 h after
bacterial challenge (instead of> 16 h after challenge with the
1090) , Therefore, 3 days oftreatment with either amoxicillin/
clavulanate or vancomycin failed, even when started as soon
as 12 h after infection (figure 4).
Experiments with the homogeneously resistant derivative
MRSE 1386-Hom. Since only 2-6 X 10- 5of the heteroge-
neously resistant bacteria expressed high-level methicillin re-
sistance at the onset of therapy, the question arose as to
whether the efficacy ofamoxicillin/clavulanate was exagger-
ated as a result of relatively few highly resistant bacteria in
the vegetations at the onset oftherapy. Therefore, the experi-
ments described above were repeated in rats challenged with
105 cfu (1090) of the homogeneously resistant derivative
MRSE I386-Hom. As mentioned in Materials and Methods,
the homogeneous character of this organism was stable in
vitro. This also appeared to be true in vivo, as the whole
bacterial population in the vegetations expressed high-level
methicillin resistance at the beginning of treatment. Oespite
this, amoxicillin/clavulanate started either 12 or 16 h after
infection successfully treated 84% and 78% of the animals,
respectively (P < 10-4 and 10- 3 compared with controls,
respectively). Consequently, it appeared that the efficacy of
amoxicillin/clavulanate had not been overestimated by the
heterogeneous nature of the clinical isolates.
Survival ofbacteria in the spleens. Spleen cultures tended
>10h
NOTE. NO, not determined.
* Arnoxicillin/clavulanate vs. vancomycin. NS. not significant.
Inoculum. time of Amoxicillin/
treatment onset Flucloxacillin clavulanate Vancomycin p*
No. spleens culture-positive/total (%)
1090 ( I05 cfu)
12 h 20/20 (100) 1/42 (2) 10/29 (34) <.001
16 h NO 5/44 (II) 11/29 (38) <.05
24 h NO 13/33 (39) 15/30 (50) NS
10 X 1090 (10 6 cfu)
12 h NO 0/9 7/12 (58) <.05
16 h NO 1/5 (20) 5/8 (62) NS
to be more frequently sterile in rats treated with amoxicillinj
clavulanate than in rats treated with vancomycin. The trend
was observed at each treatment time and for both inoculum
sizes (table 3). However, the differences between groups
treated with amoxicillinjclavulanate and vancomycin were
statistically significant only when therapy was started at ei-
ther 12 or 16 h after challenge with the 10 90 or at 12 h after
challenge with 10 X 10 90 (table 3).
In vitro time-kill curves. Since cardiac vegetations are con-
sidered devoid ofhost defense mechanisms [28, 29], the ther-
apeutic results described above are likely to result almost
exclusively from antibiotic-induced bacterial killing in the
vegetations. Thus, it must be possible to mirror the results
obtained in vivo in time-kill curves determined in vitro. The
results of such an experiment (using strain MRSE 1386) are
shown in figure 5. During the logarithmic phase of growth,
both amoxicillinjclavulanate and vancomycin (used at con-
centrations mimicking the peak serum levels in vivo) were
highly bactericidal over a large range of bacterial densities,
which encompassed several orders ofmagnitude. In contrast,
as bacterial growth came to a halt, antibiotic-induced killing
abruptly decreased while bacterial densities in the medium
remained stable (between 108 and 109 cfu/rnl.). Thus, as was
the case in vivo, antibiotic-induced killing in vitro depended
essentially on the rate of bacterial growth, not on bacterial
densities in the medium. Similar results were also observed
with the 2 other clinical isolates ofMRSE. Note that the late
regrowth of bacteria in vancomycin-treated cultures (figure
5B) was not due to the emergence of resistant organisms but
to the progressive loss of efficiency of the drug, as deter-
mined using an agar diffusion bioassay. Indeed, after 48 h of
incubation, the antibiotic activity of vancomycin in the cul-
ture supernatants had decreased by 10 times, whereas that of
amoxicillinjclavulanate had decreased only by 2 times.
Discussion
In the present experiments, amoxicillinjclavulanate was
as effective as vancomycin against experimental endocarditis
Table 3. Number of rats with positive spleen cultures in antibi-
otic-treated animals.
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Figure 5. Time-kill curves showing bactericidal acuvity of
amoxicillin/clavulanate (A) and vancomycin (B) against methicil-
lin-resistant S. epidermidis isolate 1386. Cultures were treated at
different time points (arrows) with antibiotic concentrations re-
flecting peak serum level. Similar results were obtained with iso-
lates 4890 and 1468. 0, untreated control cultures; ., antibiotic-
treated cultures. Late regrowth of bacteria in (B) was due not to
emergence of resistant organisms but to progressive loss of effi-
ciency of drug (after 48 h of incubation, antibiotic activity of van-
comycin culture supernatants, as determined by bioassay, had de-
creased by 10 times, whereas that of amoxicillin/clavulanate had
decreased by only 2 times).
due to both heterogeneously and homogeneously resistant
strains of MRSE. These results are reminiscent of those ob-
tained in experimental endocarditis due to MRSA, where
amoxicillin/clavulanate was also equivalent to vancomycin
[II, 12]. In addition, in the present experiments the spleens
of animals treated with amoxicillin/clavulanate were sterile
more frequently than were those ofanimals receiving vanco-
mycin. While the reason(s) for this difference is speculative
(e.g., do amoxicillin/clavulanate and vancomycin interfere
differently with bacterial killing in the spleen"), the results
underline the efficacy of the ,B-lactam combination in this
setting.
The finding is ofinterest because the clustering ofmultiple
antibiotic resistance genes in methicillin-resistant staphylo-
cocci has brought these organisms to the verge of becoming
totally resistant to any available drugs. Therefore, it is essen-
tial to broaden our therapeutic armamentarium so we can
treat infections due to these pathogens without selecting resis-
tance against one ofthe last nonexperimental antibiotics that
is still effective, that is, vancomycin.
On the basis of these results, it might be envisioned to test
amoxicillin/clavulanate in patients infected with methicillin-
resistant staphylococci. Ideally, such a study should first be
done in patients with MRSE infections, because these organ-
isms produce much less severe diseases than do MRSA while
sharing the mechanism(s) of resistance to methicillin. Sev-
eral arguments suggest that such a trial might be feasible.
First, in the present setting, amoxicillin/clavulanate was as
effective as vancomycin in experiments in which both drugs
were administered to the animals in doses that strictly mim-
icked the human pharmacokinetics of the antibiotics. Sec-
ond, failures after experimental treatment with amoxicillin/
clavulanate did not select for more resistant bacteria in
animals, thus limiting the risk ofsuch occurrence in humans.
Third, coagulase-negative staphylococci tend to produce
smaller amounts of penicillinase than does S. aureus [30],
which may be important because it has been shown that pro-
duction of large quantities of penicillinase by MRSA might
decrease the efficacy ofamoxicillin/clavulanate in the model
ofexperimental endocarditis [12]. Finally, S. epiderrnidistyp-
ically produces relatively indolent infections (in contrast to
S. aureus), ensuring a relatively safe time in which to evalu-
ate and readjust therapy in patients with potential treatment
failures. Therefore, it might be possible to safely assess the
efficacy of amoxicillin/clavulanate against MRSE infections
in humans.
A second observation in the present study is the abrupt
loss of efficacy of both amoxicillin/clavulanate and vanco-
mycin as bacterial growth came to a halt in the vegetations.
Decreased killing ofslow-growing bacteria by cell-wall inhibi-
tors (as well as by other antibiotics) is well known in vitro
and has been referred to as phenotypic tolerance [31]. Pheno-
typic tolerance undoubtedly also occurs in vivo [31, 32] but
is difficult to demonstrate in the complex biologic environ-
ment of animal models of infections. Poorly controlled fac-
tors such as host defense mechanisms, progressive alterations
in the nature of the infective lesions, or alterations in the
diffusion or stability of antibiotics in situ may influence the
results either positively or negatively.
In this regard, experimental endocarditis is an advan-
tageous model because cardiac vegetations are virtually de-
void of cellular host defenses [28, 29]. In addition, in the
present experiments, the failure of delayed therapy (started
at 24 h) was not the result ofmajor changes in the vegetation
or alteration of local drug diffusion for two reasons. The
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mass of the valvular lesions did not increase between 16 and
24 h after infection (data not shown) and the correlation
between the abrupt switch off ofantibiotic-induced bacterial
killing and the slowdown ofbacterial growth at high bacterial
densities was fully reproducible in liquid cultures in vitro,
where antibiotic diffusion is not a major issue. Thus, the
present experiments clearly illustrate the phenomenon of
phenotypic tolerance in vivo. The results also provide a plau-
sible explanation for previously reported treatment failures
associated with high bacterial densities in the vegetations
[33, 34]. Such treatment failure (sometimes attributed to an
ill-defined inoculum effect) may largely result from slow
growth (i.e., a state of phenotypic tolerance) of bacteria in
situ rather than from high bacterial densities per se. In the
present experiments, a genuine inoculum effect was illus-
trated in animals challenged with large bacterial inocula ( 10
X ID9o) : Halt in growth due to high bacterial densities in situ
was attained sooner than after injection of smaller inocula,
resulting in phenotypic tolerance and decreased therapeutic
efficacy even when treatment was started as early as 12 h
after infection. Therefore, it is crucial to precisely define
both the size of bacterial inoculum and the timing of therapy
onset in order to obtain reproducible results in experimental
models of infection.
In conclusion, the good efficacy of arnoxicillin/clavula-
nate treatment against experimental endocarditis due to
MRSE, associated with its previously reported success
against MRSA infections [11, 12], suggests that this fj-lactam
combination might be used in clinical trials to treat patients
with MRSE infections. In addition, our observations high-
light the importance of phenotypic tolerance in vivo. The
rapid slowdown of in situ bacterial growth rates observed
between 107 and 108 cfu/g of tissue makes it difficult to
merely rely on bacterial densities in the vegetations to ensure
reproducible results. It is crucial to precisely define the exper-
imental conditions in animal models of infections, as slight
variations in the size ofbacterial inoculum or in the timing of
therapy may dramatically alter the nature of the experimen-
tal results, without influencing the most commonly tested
parameter in experimental endocarditis, the bacterial densi-
ties in the cardiac vegetations.
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